Spruce Biosciences, Inc. Payments for Repurchase of Initial Public Offering
Spruce Biosciences, Inc. (SPRB) reported Payments for Repurchase of Initial Public Offering of $2.90 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2021-03-22
- Spruce Biosciences, Inc. payments for repurchase of initial public offering for fiscal 2020 was $2.90M.
| Period end | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|
| 2020-12-31 | $2.90M 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |